FIELD: biotechnology.
SUBSTANCE: disclosed are recovered antibodies and antigen-binding fragments thereof, which bind to human bile salt stimulated lipase (hBSSL). Antibodies and their antigen-binding fragments bind to an epitope located in the N-terminal part of hBSSL and identified as containing amino acid residues 7–12 and amino acid residues 42–55. Also disclosed are polynucleotides coding said antibodies or fragments thereof, expression vectors and host cells containing said polynucleotides, a method of producing antibodies. Invention also relates to the medical use of the antibodies and/or antigen-binding fragments thereof, particularly in the treatment or diagnosis of inflammatory conditions, as well as to related pharmaceutical compositions.
EFFECT: invention provides specific binding of BSSL without significant effect on enzymatic activity and with low risk of immunogenicity.
41 cl, 33 dwg, 29 tbl, 24 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CD40 LIGAND THERAPEUTIC ANTIBODIES | 2018 |
|
RU2770209C2 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING SUBSTITUTE FUNCTIONAL ACTIVITY OF BLOOD COAGULATING FACTOR VIII CO-FACTOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SPECIFIED MOLECULE AS ACTIVE INGREDIENT | 2018 |
|
RU2812909C2 |
| PROCOAGULANT ANTIBODIES | 2018 |
|
RU2810094C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
| ANTI-CD137 ANTIGEN-BINDING MOLECULES AND USE THEREOF | 2019 |
|
RU2829536C2 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES AND METHODS OF THEIR USE | 2019 |
|
RU2800779C2 |
| COMBINATIONS OF ANTIBODIES TO STAPHYLOCOCCUS AUREUS | 2019 |
|
RU2804815C2 |
